Vertex Pharmaceuticals Incorporated  

(Public, NASDAQ:VRTX)   Watch this stock  
Find more results for VRTX
-2.03 (-1.50%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 132.12 - 137.00
52 week 71.46 - 137.26
Open 136.58
Vol / Avg. 2.17M/1.92M
Mkt cap 32.75B
P/E 188.54
Div/yield     -
EPS 0.71
Shares 249.07M
Beta 1.65
Inst. own 100%
Jul 25, 2017
Q2 2017 Vertex Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 15, 2017
Vertex Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 13, 2017
Vertex Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 8, 2017
Vertex Pharmaceuticals Inc Annual Shareholders Meeting
May 23, 2017
Vertex Pharmaceuticals Inc at UBS Global Healthcare Conference - Webcast
Apr 27, 2017
Q1 2017 Vertex Pharmaceuticals Inc Earnings Call - Webcast
Apr 27, 2017
Q1 2017 Vertex Pharmaceuticals Inc Earnings Release
Mar 29, 2017
Vertex Pharmaceuticals Inc Business Update Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 34.92% -4.94%
Operating margin 37.89% 0.58%
EBITD margin - 4.26%
Return on average assets 34.26% -3.11%
Return on average equity 74.81% -10.69%
Employees 2,150 -
CDP Score - -


50 Northern Ave
BOSTON, MA 02210-1862
United States - Map
+1-617-3416393 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Officers and directors

Jeffrey M. Leiden M.D. Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Ian F. Smith CPA Chief Financial Officer, Chief Operating Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Michael J. Parini J.D. Executive Vice President, Chief Legal and Administrative Officer
Age: 42
Bio & Compensation  - Reuters
David Altshuler M.D., Ph.D. Executive Vice President - Global Research, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Stuart A. Arbuckle Executive Vice President, Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Jeffrey A. Chodakewitz M.D. Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Amit K. Sachdev J.D. Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
Age: 49
Bio & Compensation  - Reuters
Paul M. Silva Senior Vice President, Corporate Controller
Age: 51
Bio & Compensation  - Reuters
Bruce I. Sachs Lead Director, Independent Director
Age: 57
Bio & Compensation  - Reuters
Elaine S. Ullian Co-Lead Independent Director
Age: 69
Bio & Compensation  - Reuters